Hiroki Uchikawa, Koki Kameno, Keitaro Kai, Sosho Kajiwara, Kana Fujimori, Ken Uekawa, Yukio Fujiwara, Akitake Mukasa, Shokei Kim-Mitsuyama, Yu Hasegawa. Pretreatment with Clodronate Improved Neurological Function by Preventing Reduction of Posthemorrhagic Cerebral Blood Flow in Experimental Subarachnoid Hemorrhage. Neurocritical care. 2023
Koki Kameno, Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Hiroki Uchikawa, Akitake Mukasa, Shokei Kim-Mitsuyama. Loss of body weight in old 5xFAD mice and the alteration of gut microbiota composition. Experimental gerontology. 2022. 166. 111885-111885
Hiroaki Kusaka, Daisuke Sueta, Nobutaka Koibuchi, Yu Hasegawa, Takashi Nakagawa, BoWen Lin, Hisao Ogawa, Shokei Kim-Mitsuyama. Corrigendum to: LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone. American journal of hypertension. 2022. 35. 2. 208-208
Yu Hasegawa, Yushin Takemoto, Kenyu Hayashi, Koki Kameno, Shokei Kim-Mitsuyama. The endogenous and exogenous brain-derived neurotrophic factor plays pivotal roles in the pathogenesis of stroke onset in high salt-loaded hypertensive rats. Experimental Gerontology. 2021. 147
徳永 信行, 中村 太志, 光山 勝慶, 辻田 賢一. PKG1α酸化はチロシン水酸化酵素のリン酸化反応の誘発および交感神経調節不全の末梢抵抗から至る食塩感受性高血圧症の一因となる(PKG1α Oxidation Induces Tyrosine Hydroxylase Phosphorylation and Contributes to Salt Sensitive Hypertension Through Sympathetic-dysregulated Peripheral Resistance). 日本内分泌学会雑誌. 2021. 96. 4. 1103-1103
Anemia is an independent risk factor for cardiovascular and renal events in hypertensive patients subjected to antihypertensive therapy: a subgroup analysis of ATTEMPT-CVD randomized trial
(Nephro Update Europe 2019)
Are RAS inhibitors necessary for all patients with diabetes and chronic kidney disease?
(Hypertension Seoul 2016 2016)